Conquering the "Silver Tsunami": Insight Examines the Landscape and Trends of Innovative Drug R&D for Alzheimer's Disease at ICNS 2026

On August 13-14, the 8th Small-Molecule Innovative Drug Summit (SIT 2026) and the 6th In-Depth Forum on Central Nervous System Drug Development (ICNS 2026) were held concurrently in Nanjing.

As a global pharmaceutical data intelligence and analytics platform built on reliable, traceable data, DXY Insight Database was featured at the event, engaging with industry professionals from innovative pharmaceutical companies, research institutions, investment firms, CROs, and other sectors. Discussions focused on key topics including small-molecule drug R&D, clinical translation, commercialization pathways, and strategic decision-making.

This year's ICNS Forum focused on the latest developments in CNS drug development, clinical translation, and commercialization. Covering areas ranging from neurodegenerative diseases to psychiatric disorders, the forum featured in-depth discussions on cross-border collaboration, global strategies, technological innovation, and other critical issues.

Jiang Peng, Senior Pharmaceutical Industry Analyst at DXY Insight Database, delivered a presentation titled "Conquering the 'Silver Tsunami': Insights into the Landscape and Trends of Innovative Drug R&D for Alzheimer's Disease." The presentation provided a systematic overview of the evolving Alzheimer's disease drug development landscape, examining disease burden, unmet diagnostic and treatment needs, the value of disease-modifying therapies, future R&D directions, and the development of an integrated treatment, reimbursement, and care ecosystem.

A Growing Disease Burden and Persistent Unmet Need

The presentation noted that, against the backdrop of accelerating population aging, the number of people living with Alzheimer's disease has surpassed 10 million, with the continued growth of the aging population further expanding the potential patient pool. At the same time, delayed recognition of clinical symptoms, complex and costly diagnostic pathways, and insufficient long-term care capacity remain significant challenges. As a result, many patients miss the optimal window for early intervention, while families and society face a substantial overall burden.

DMTs Are Changing the Treatment Paradigm

On the treatment side, the emergence of disease-modifying therapies (DMTs) has driven a historic shift in Alzheimer's disease treatment, from symptomatic management toward slowing disease progression, creating a new value inflection point for disease intervention. However, current anti-amyloid-beta monoclonal antibodies are primarily indicated for early-stage patients with pathologically confirmed disease, with treatment goals focused more on slowing decline than restoring function. Requirements related to ARIA risk, infusion procedures, safety monitoring, and repeated MRI examinations further increase the barriers to treatment.

The presentation also emphasized that the commercial potential of existing DMTs cannot simply be equated with the total number of patients. The true ceiling for market adoption is determined by the number of patients who are identifiable, treatable, and able to afford treatment. Beyond the cost of the therapy itself, associated requirements and expenses, including upfront biomarker screening, pathological confirmation through amyloid PET or cerebrospinal fluid testing, and repeated MRI-based safety monitoring, can significantly affect patient access and the capacity of healthcare and reimbursement systems.

Where Is Alzheimer's Innovation Heading?

Looking ahead, Alzheimer's disease diagnosis and treatment are expected to move toward earlier detection and increasingly stratified approaches. Blood-based biomarkers such as p-tau217 may play a role in initial screening and referral, while PET and CSF testing can support pathological confirmation. MRI and genetic risk assessment may further inform treatment decisions and safety monitoring.

Drug development is also expected to move beyond single-target approaches toward multi-target strategies and more patient-friendly methods of drug delivery. Companies are expanding their pipelines across multiple mechanisms, including Tau, neuroinflammation, synaptic protection, and metabolic dysfunction, while actively exploring treatment modalities such as subcutaneous injections and oral small molecules.

From Innovation to Real-World Adoption

As innovative Alzheimer's disease therapies continue to advance toward clinical translation and broader market adoption, the industry will also need to build a more comprehensive, end-to-end ecosystem spanning diagnosis, treatment, reimbursement, and long-term care. Connecting key stages from community screening and memory clinics to pathological confirmation, treatment, safety monitoring, long-term care, and reimbursement, while demonstrating value through real-world functional outcomes, long-term safety data, and risk-sharing payment models, will be critical to ensuring that innovative therapies can ultimately benefit more patients.

At the forum, DXY Insight Database also held in-depth discussions with attendees on topics including the CNS drug R&D landscape, Alzheimer's disease pipeline progress, clinical trial developments, competitive dynamics, and market access trends. These discussions highlighted the database's capabilities in disease-area research, innovative drug pipeline screening and analysis, clinical development tracking, pharmaceutical intelligence analysis, and R&D decision support.

As Alzheimer's disease research and drug development continue to evolve, data-driven pharmaceutical intelligence will play an increasingly important role in helping industry stakeholders identify emerging opportunities, understand competitive dynamics, and make better-informed R&D and commercial decisions.